- Home
- RDHL vs SLE Comparison
RDHL vs SLE Comparison
Compare RDHL & SLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- SLE
- Stock Information
- Founded
- RDHL 2009
- SLE 2014
- Country
- RDHL Israel
- SLE United States
- Employees
- RDHL N/A
- SLE N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- SLE Services-Misc. Amusement & Recreation
- Sector
- RDHL Health Care
- SLE Consumer Discretionary
- Exchange
- RDHL Nasdaq
- SLE Nasdaq
- Market Cap
- RDHL 4.3M
- SLE 6.5M
- IPO Year
- RDHL N/A
- SLE 2019
- Fundamental
- Price
- RDHL $2.15
- SLE $5.82
- Analyst Decision
- RDHL
- SLE Strong Buy
- Analyst Count
- RDHL 0
- SLE 2
- Target Price
- RDHL N/A
- SLE $100.00
- AVG Volume (30 Days)
- RDHL 18.4K
- SLE 157.3K
- Earning Date
- RDHL 08-28-2025
- SLE 08-13-2025
- Dividend Yield
- RDHL N/A
- SLE N/A
- EPS Growth
- RDHL N/A
- SLE N/A
- EPS
- RDHL N/A
- SLE N/A
- Revenue
- RDHL $8,042,999.00
- SLE $14,691,000.00
- Revenue This Year
- RDHL $381.91
- SLE N/A
- Revenue Next Year
- RDHL N/A
- SLE $30.36
- P/E Ratio
- RDHL N/A
- SLE N/A
- Revenue Growth
- RDHL 23.17
- SLE N/A
- 52 Week Low
- RDHL $1.71
- SLE $3.91
- 52 Week High
- RDHL $20.28
- SLE $65.60
- Technical
- Relative Strength Index (RSI)
- RDHL 64.10
- SLE 51.50
- Support Level
- RDHL $2.00
- SLE $4.71
- Resistance Level
- RDHL $2.08
- SLE $6.81
- Average True Range (ATR)
- RDHL 0.09
- SLE 0.65
- MACD
- RDHL 0.03
- SLE 0.34
- Stochastic Oscillator
- RDHL 100.00
- SLE 65.86
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About SLE Super League Enterprise Inc.
Super League Enterprise Inc is the rocket ship to the metaverse. It is a creator and publisher of content experiences and media solutions across the globe's immersive platforms. Its solutions provide incomparable access to massive audiences that gather in immersive digital spaces to socialize, play, explore, collaborate, shop, learn, and create. The company offers a complete range of development, distribution, monetization, and optimization capabilities designed to engage users through dynamic, energized programs. It generates revenue from advertising, including immersive game world and experience publishing and in-game media products, direct-to-consumer offers, including in-game items, e-commerce, game passes and ticketing and digital collectibles, and content and technology.